This policy governs coverage and medical necessity criteria for implantable vagus nerve stimulators and nonimplantable/transcutaneous vagus and trigeminal nerve stimulation devices, primarily for epilepsy and other indications, affecting UnitedHealthcare members and their providers.
Policy Summary
PayerUnitedHealthcare
PolicyVagus and External Trigeminal Nerve Stimulation
Policy CodePolicy SURGERY 073.29
Change TypeMaterial updates to device categorization and coverage wording (implantable VNS affirmedtranscutaneous devices recategorized as not medically necessary)
Effective DateFeb 1, 2025
Next Review Date
Key ActionObtain prior authorization and document failure of two or more antiepileptic drug trials (or intolerable side effects) when requesting implantable VNS for epilepsy.
Replaced language to affirm that implantable vagus nerve stimulators are proven and medically necessary for treating epilepsy in individuals meeting the listed conditions.
Removed examples of responsive (closed‑loop) VNS implants and revised language to categorize transcutaneous (non‑implantable) vagus nerve stimulation devices as unproven/not medically necessary.
Removed specific example device names for external/transcutaneous trigeminal nerve stimulation (e.g., Monarch, Cefaly) from the list of devices.
Updated Description of Services, Clinical Evidence, FDA, and References sections to reflect the most current information.
implantable VNS covered for epilepsyPrimary covered indication
t‑VNS/TNS not medically necessaryNoninvasive devices stance
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.
61 studies
Meta-analyses
Level CAAN recommendation strength
2 AED failuresILAE threshold
Coverage Criteria and Evidence Summary
Implantable VNS — Medical Necessity
Covered when ALL of the following are met:
Implantable VNS — Medical Necessity: The individual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or refuses epilepsy surgery after Shared Decision Making; AND medically refractory epileptic seizures with failure of two or more trials of single or combination antiepileptic drug therapy or intolerable side effects of antiepileptic drug therapy; AND no history of left or bilateral cervical vagotomy (a contraindication to VNS).failure of two or more trials of antiepileptic drug therapy
AAN practice parameters support VNS for adults and adolescents >12 years with medically intractable partial seizures when resective surgery is not appropriate; monitor infection risk especially in children.
External/Transcutaneous VNS/TNS — Not Medically Necessary
Not medically necessary for all indications due to insufficient evidence:
External/Transcutaneous VNS/TNS — Not Medically Necessary: External or transcutaneous (non‑implantable) trigeminal nerve stimulation devices and transcutaneous (non‑implantable) vagus nerve stimulation devices are considered unproven and not medically necessary for preventing or treating all indications (including but not limited to ADHD, epilepsy, depression, headache).insufficient evidence
Examples of non‑implantable devices include cervical nVNS (gammaCore) and supraorbital eTNS (Cefaly); these device types are judged unsupported for routine coverage for the listed indications pending stronger evidence.
Evidence summaries and indication-specific coverage considerations
Summarized clinical evidence and guidance by indication:
Epilepsy (implantable VNS): AAN guidance supports VNS for adults and adolescents >12 years with medically intractable partial seizures who are not candidates for potentially curative resection; VNS provides modest seizure reduction compared with new AEDs and less than mesial temporal lobectomy, and is appropriate when medication failure persists and surgery is unsuitable.age >12; failure of two or more AED trials
Evidence ranked as effective and safe by AAN; increased infection vigilance in children noted
Treatment‑Resistant Depression (implantable VNS): Overall evidence is limited: observational registry data (e.g., Aaronson 2017, 795 patients) show improved long‑term response/remission versus treatment‑as‑usual, but randomized trial evidence is sparse and mixed; NICE recommends use only with special arrangements and further RCTs.multiple prior treatment failures as per registry definitions
AHRQ and systematic reviews highlight study limitations and the need for larger randomized trials
Summary of clinical evidence and guideline positions by indication:
Cluster headache (episodic vs chronic): Randomized trials and meta‑analyses show noninvasive VNS (nVNS; e.g., gammaCore) is effective for acute treatment of episodic cluster headache but not for chronic cluster headache; prophylactic adjunctive nVNS showed reduced attack frequency in some studies (PREVA) though study designs and durations limit certainty.benefit demonstrated for episodic cluster headache; not for chronic cluster headache
NICE recommends continuing gammaCore only if symptoms reduce within the first 3 months; adverse events generally mild
Migraine — acute treatment: Some randomized sham‑controlled trials (e.g., Tassorelli 2018) found nVNS or eTNS superior to sham for pain freedom/relief at early time points (30–60 minutes) in episodic migraine; devices have FDA clearance for acute use per AHS positions.pain freedom/relief within 30–60 minutes in trials
Effect sizes modest and larger trials recommended
Coverage notes by device type and indication
Coverage stance varies by device type and indication; key points from policy updates and external guidance:
Implantable VNS for epilepsy: Implantable vagus nerve stimulators are affirmed as proven and medically necessary for treating epilepsy in individuals who meet the listed clinical conditions (see implantable VNS criteria).
Policy language revised to explicitly state implantable VNS necessity for qualifying epilepsy indications.
Transcutaneous/external VNS and trigeminal stimulation: Transcutaneous (non‑implantable) vagus nerve stimulation devices and external/transcutaneous trigeminal nerve stimulation have mixed or limited evidence depending on indication: NICE supports supraorbital transcutaneous stimulation for acute migraine only with special arrangements and finds preventive evidence inadequate; AAP does not recommend eTNS for ADHD due to sparse evidence.
Policy revisions removed some device examples from the proven list and categorized non‑implantable devices as unproven/not medically necessary for routine coverage.
Vagus nerve blocking for the treatment of obesity is not managed under this policy. Refer requests for vagus nerve blocking for obesity to the Clinical Policy titled Bariatric Surgery for coverage determination and medical necessity assessment.
External or transcutaneous (non‑implantable) vagus nerve stimulation (t‑VNS/nVNS) and external/transcutaneous trigeminal nerve stimulation (eTNS) are considered unproven and not medically necessary for preventing or treating most indications due to insufficient evidence. Examples of indications judged unsupported include ADHD, epilepsy, depression, and headache. Larger, higher‑quality studies are needed to establish safety, efficacy, and long‑term outcomes before routine coverage is appropriate.
There is insufficient evidence to support the use of transcutaneous vagus nerve stimulation for non‑headache indications such as atrial fibrillation, premature ventricular contractions, and other cardiac or systemic conditions. Existing studies are limited by small sample sizes and weak designs, and further randomized trials are required to demonstrate clinical benefit and safety.
The policy updates revised the list of device types categorized as unproven and not medically necessary. In these revisions, some prior example device types (for example, earlier references to responsive/closed‑loop VNS implants) were removed and the focus was clarified to identify transcutaneous (non‑implantable) VNS devices as unproven/not medically necessary for routine use.
External or transcutaneous trigeminal nerve stimulation devices and transcutaneous vagus nerve stimulation devices are listed as unproven and not medically necessary for treating all conditions in this policy. For migraine specifically, NICE recommends use of supraorbital transcutaneous stimulation for acute migraine only with special arrangements for governance, consent, and audit or research; evidence for preventive use is inadequate.
Vagus nerve stimulation—whether implantable or transcutaneous—has been studied for a range of other conditions (for example, Alzheimer disease, autism spectrum disorder, OCD, chronic pain and autoimmune disorders), but available data are limited. For these other conditions, evidence quality and quantity are insufficient to support routine coverage; transcutaneous VNS specifically remains investigational pending more robust clinical trial data.
For some applications of external trigeminal nerve stimulation (eTNS) and transcutaneous VNS (t‑VNS)—for example, migraine prevention—published analyses report mixed or low‑quality evidence. NICE advises that acute treatment evidence may be adequate only under special arrangements and that preventive indications lack sufficient quality data; therefore routine coverage as a proven therapy is not supported for these indications.
Transcutaneous (non‑implantable) vagus nerve stimulation devices are specifically identified in the policy revisions as among device types categorized as unproven and not medically necessary. This revision removed prior example device names from the proven list and clarifies that non‑implantable VNS devices are not considered proven for routine coverage.
Billing Codes and Coding References
Surgical CPT CodesCPT
61885
Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array.
61886
Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to 2 or more electrode arrays.
64553
Percutaneous implantation of neurostimulator electrode array; cranial nerve.
64568
Open implantation of cranial nerve (e.g-, vagus nerve) neurostimulator electrode array and generator pulse.
64570
Removal of cranial nerve (vagus nerve) neurostimulator electrode array and pulse generator (e.g ,
HCPCS/Revenue/LT Codesmixed
A4541
Monthly supplies for use of device coded at E0733.
E0733
Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve.
E0735
Noninvasive vagus nerve stimulator.
E0770
Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified.
E1399
Durable medical equipment, miscellaneous.
L8679
Implantable neurostimulator; pulse generator, any type.
Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver.
L8685
Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
1–10 of 13
1/2
Transcutaneous VNS FDA product codesmixed
PKR
FDA product code referenced for Transcutaneous (Non-Implantable) Vagus Nerve Stimulation devices
QAK
FDA product code referenced for Transcutaneous (Non-Implantable) Vagus Nerve Stimulation devices
External/Trigeminal stimulation FDA product codesmixed
PCC
FDA product code referenced for External or Transcutaneous Trigeminal Nerve Stimulation devices
QGL
FDA product code referenced for External or Transcutaneous Trigeminal Nerve Stimulation devices
Antiepileptic drug trials — requirement for implantable VNS
Required medication trialsFailure of two or more trials of single or combination antiepileptic drug therapy (or intolerable side effects) before considering implantable VNS.
Surgical candidacyIndividual is not a candidate for epilepsy surgery, has failed epilepsy surgery, or refuses epilepsy surgery after Shared Decision Making.
ContraindicationNo history of left or bilateral cervical vagotomy (FDA‑recognized contraindication).
Prior Authorization, Documentation, and Denial Risks
Prior Authorization
Prior authorization required
Prior authorization is required when billing the listed CPT and HCPCS/LT codes for implantable neurostimulator devices and related supplies. Refer to the member-specific benefit plan and prior-authorization tools; documentation supporting medical necessity must be submitted with the request.
Affected codes include implantable neurostimulator and supply codes (see Applicable Codes lists: CPT 61885, 61886, 64553, 64568, 64570; HCPCS/LT L8679, L8680, L8682, L8683, L8685-L8688; E0733, E0735, E0770; A4541; E1399).
Prior authorization requirements and plan terms must be verified on the member’s benefit plan; UnitedHealthcare may use InterQual or similar tools to support decisions.
Prior Authorization
Prior authorization: VNS for epilepsy and TRD
Prior authorization requests for implantable VNS for epilepsy or treatment‑resistant depression (TRD) must document that the member meets established clinical criteria for the targeted condition.
For epilepsy: documentation that seizures are medically intractable/drug‑resistant — defined as failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug (AED) schedules (whether as monotherapies or in combination).
Background and Scope
BACKGROUND: Vagus nerve stimulation (VNS) delivers electrical impulses to the brain via the vagus nerve using an implanted generator and leads. Non‑implantable (transcutaneous) VNS and external trigeminal nerve stimulation deliver stimulation through the skin; mechanisms are not fully understood, and non‑implantable approaches are under investigation for multiple indications but are currently considered unproven for the majority of uses.
Definitions and Device Terminology
Shared Decision Making — definition and context
DefinitionShared Decision Making is a process in which a provider and a patient (including caregivers/family) work together to make a health care decision considering evidence, provider expertise, and patient values and preferences.
ComponentsCompares benefits, harms, and risks of options and discusses what matters most to the patient.
Source guidance exampleReferenced: AHRQ, The SHARE Approach (2014).
Non-implantable VNS/TNS — definition and examples
DefinitionNon-implantable VNS/TNS are external or transcutaneous devices that deliver electrical stimulation to the vagus or trigeminal nerve through the skin (noninvasive).
Examples (documented)gammaCore (noninvasive handheld transcutaneous VNS) and Cefaly / Monarch eTNS systems (external trigeminal stimulation).
Policy Summary
PayerUnitedHealthcare
PolicyVagus and External Trigeminal Nerve Stimulation
Policy CodePolicy SURGERY 073.29
Change TypeMaterial updates to device categorization and coverage wording (implantable VNS affirmedtranscutaneous devices recategorized as not medically necessary)
Effective DateFeb 1, 2025
Next Review Date
Key ActionObtain prior authorization and document failure of two or more antiepileptic drug trials (or intolerable side effects) when requesting implantable VNS for epilepsy.
Non‑implantable/Transcutaneous VNS and Other Indications: For many other indications (e.g., Alzheimer disease, autism spectrum disorder, OCD, chronic pain, cardiac arrhythmia, multiple psychiatric and autoimmune conditions), current evidence is insufficient to support routine use of VNS or transcutaneous VNS; further well‑designed trials are required.insufficient evidence
Policy treats these indications as investigational or not medically necessary pending more data
Migraine — preventive treatment: Preventive trials (e.g., PREMIUM, Diener 2019; Najib 2022) produced mixed results: intent‑to‑treat analyses often not superior to sham, but adherent‑subgroup or post hoc analyses sometimes show benefit; limitations include sham device activity, suboptimal adherence, and underpowered samples.adherence‑dependent signals observed
Systematic reviews conclude evidence is insufficient or low quality for broad preventive claims
Other neurologic and non‑neurologic conditions: Preliminary or small studies exist for eTNS/t‑VNS in epilepsy, ADHD, depression, atrial fibrillation and other conditions, but evidence quality is low and sample sizes small; routine clinical use is not supported without larger, rigorous trials.insufficient evidence
Systematic reviews and guideline bodies (NICE, AAP) call for more data
For epilepsy: documentation the individual is not a candidate for epilepsy resective surgery, has failed epilepsy surgery, or has discussed and refused surgery after shared decision making.
For TRD: documentation of failure or intolerance to an adequate course of evidence‑based pharmacotherapy and other indicated treatments per specialty standards (include prior medication trials).
Prior Authorization
Short trial and documented benefit required
Continuation of therapy (permanent implant) should be limited to patients demonstrating clinical benefit within a short trial period. If benefit is not demonstrated during an initial short trial, continuation or implantation should not be pursued.
Example operational expectation: assess clinical response within approximately 3 months of device activation; document seizure frequency reduction or functional improvement.
For cluster headache/migraine devices (nVNS/gammaCore), NICE recommends continuing therapy only for people whose symptoms reduce within the first 3 months.
Documentation Required
Required documentation
Medical records documentation may be required to assess whether the member meets the clinical criteria for coverage; documentation does not guarantee coverage.
Include relevant history, prior therapy trials (medication names, doses, durations), imaging and surgical candidacy documentation, and informed/shared decision‑making notes.
When applicable, include documentation of intolerance or adverse effects to prior pharmacotherapies.
Documentation Required
Epilepsy candidate documentation
For epilepsy cases, prior authorization should include clear documentation that the member is a candidate for VNS: drug‑resistant epilepsy per ILAE (failed ≥2 adequate AED trials), and documentation regarding epilepsy surgery candidacy or refusal.
List of AED trials with doses and dates showing inadequate response or intolerable side effects.
Evidence that the patient is not a surgical candidate, failed prior epilepsy surgery, or has documented discussion and refusal of resective epilepsy surgery (shared decision making).
Documentation Required
Baseline headache diary and adherence data
For headache and migraine coverage decisions involving noninvasive/transcutaneous devices, include baseline headache/migraine diaries and treatment adherence data because trials and approvals relied on run‑in baselines and adherence to regimen.
Provide baseline headache/migraine frequency (days per month) from a run‑in period and device adherence logs or other objective adherence measures.
Document prior pharmacologic and nonpharmacologic treatment trials and outcomes.
Denial Risk
Insufficient evidence risk for non‑implantable devices
Transcutaneous (non‑implantable) vagus nerve stimulation and external trigeminal stimulation devices are considered unproven due to insufficient evidence; requests for coverage are likely to be denied under typical medical‑necessity standards.
Coverage for these device types should be denied unless exceptional plan terms or participation in approved research/special arrangements apply.
Note
Use limited to special arrangements (NICE)
Some noninvasive vagus nerve stimulation procedures have NICE recommendations limiting routine use; they should only be used with special arrangements for clinical governance, consent, and audit or research.
NICE advises using transcutaneous cervical vagus stimulation for cluster headache and migraine only within special arrangements (clinical governance, consent, audit/research).
When applicable, provide documentation of enrollment in approved clinical governance, audit, or research programs to support coverage consideration.
Prior Authorization
Prior authorization guidance
When deciding coverage, always check the member-specific benefit plan and applicable federal/state mandates; UnitedHealthcare may apply third‑party criteria (e.g., InterQual) in adjudication.
Member plan terms control benefits — prior authorization requirements, exclusions, and mandates vary by contract.
UnitedHealthcare may require submission of prior-authorization forms, clinical notes, imaging, and prior-treatment records to verify criteria.
Investigational usesBeing studied for pain, epilepsy, tinnitus, depression, ADHD, and headache indications; evidence often insufficient for routine coverage.
Definition: Drug-resistant epilepsy
ILAE definitionFailure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drug schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.
Clinical implicationUsed to define drug‑resistant epilepsy and to trigger consideration of alternative therapies (e.g., VNS) when surgery is not appropriate.
Source referenceInternational League Against Epilepsy taskforce (Tellez‑Zenteno et al., 2014).
AAN Level C — evidence definition
AAN Level C meaningPossibly effective, ineffective, or harmful; rating requires at least one Class II study or two consistent Class III studies.
Evidence thresholdAt least one Class II study or two consistent Class III studies needed to assign Level C.
InterpretationIndicates limited/conflicting evidence; conclusions should be cautious when applying to coverage decisions.
nVNS (noninvasive vagus nerve stimulation) — definition and example devices
DefinitionnVNS (noninvasive vagus nerve stimulation) delivers external stimulation to the cervical vagus nerve for acute and preventive treatment of cluster and migraine headaches.
Example devicegammaCore (ElectroCore) is a handheld prescription nVNS device referenced in trials and FDA listings.
Indications under studyAcute episodic cluster headache, episodic migraine (acute), and preventive migraine in some trials; evidence varies by indication.
eTNS / Cefaly (external trigeminal nerve stimulation) — definition and example devices
DefinitioneTNS (external trigeminal nerve stimulation, e.g., Cefaly) is transcutaneous electrical stimulation of the supraorbital/trigeminal nerve for acute and preventive migraine therapy.
Example deviceCefaly device (e‑TNS) used in randomized trials for acute migraine treatment and included in NICE guidance.
Regulatory/guidance contextNICE (2022) finds evidence adequate for acute migraine treatment under special arrangements but inadequate for prevention outside research.
t‑VNS — auricular (ear) stimulation definition and use
Definitiont‑VNS (transcutaneous vagus nerve stimulation) involves stimulation of the auricular branch of the vagus nerve at the ear for migraine management.
Clinical trial evidenceStraube et al. (2015) randomized chronic migraine patients to auricular t‑VNS and reported reductions in headache days and disability measures in per‑protocol analyses.
LimitationsStudies are small and limited; evidence quality insufficient for broad coverage for many indications.
FDA device clearance references — product codes and database guidance
FDA product codes for transcutaneous VNSPKR, QAK — product codes referenced for Transcutaneous (Non‑Implantable) VNS devices; search CDRH 510(k)/PMA databases for device listings.
FDA product codes for external/trigeminal stimulationPCC, QGL — product codes referenced for External or Transcutaneous Trigeminal Nerve Stimulation devices.
How to locate clearance infoSearch the FDA CDRH 510(k) database or PMA database by product or manufacturer name to locate marketing clearance information for specific devices.